
    
      We proposed a randomized controlled trial between 3,4-diaminopyridine and placebo .

      The main objective : improvement of fatigue by diminution of EMIF-SEP score between the arm
      treatment and placebo arm. The hypothesis tested is that the 3,4-DAP is efficacy in the
      fatigue of multiple sclerosis.
    
  